Boston Scientific Corporation News

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Participates in FDA General Issues Panel on Transvaginal Surgical Mesh for Pelvic Organ Prolapse

On February 12, 2019, the U.S. Food and Drug Administration (FDA) convened an advisory panel of experts to discuss the safety and effectiveness of surgical mesh placed transvaginally to treat pelvic organ prolapse (POP).

BOSTON SCIENTIFIC CORPORATION: VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes in Patients with Deep Venous Blockages

Today, Boston Scientific (NYSE: BSX) announced positive 12-month data demonstrating that patients who were treated with the VICI VENOUS STENT® System for iliac and femoral vein obstructions exhibited a high rate of patent, or open, target lesions.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

Boston Scientific Corporation (NYSE: BSX) and Edwards Lifesciences Corporation (NYSE: EW) today announced that the companies have reached an agreement to settle all outstanding patent disputes between the companies in all venues around the world.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Exercises Option to Acquire Millipede, Inc.

Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Millipede, Inc, a privately-held company in Santa Rosa, Calif., upon its recent successful completion of a first-in-human clinical study.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific to Participate in 37th Annual J.P. Morgan Healthcare Conference

Boston Scientific Corporation (NYSE: BSX) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 in San Francisco, California.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific to Participate in 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference

Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 in New York City.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Announces Recommended Offer to Acquire BTG plc.

Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a company headquartered in the United Kingdom, which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as acute care pharmaceuticals.

BOSTON SCIENTIFIC CORPORATION: WATCHMAN™ Wins Best Medical Technology Award

The Boston Scientific WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device has received the Prix Galien USA 2018 Award for Best Medical Technology.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Prevails in German Edwards Lifesciences Litigation

Boston Scientific Corporation (NYSE: BSX) today announced the District Court of Dusseldorf, Germany has determined that Edwards Lifesciences Corporation's Sapien 3 Ultra™ device infringed a patent – established by Symetis SA, a subsidiary of Boston Scientific – specific to the fabric used on the valve seal, specifically the German part of European Patent (EP) 2 949 292 B1.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Closes Acquisition of Augmenix, Inc.

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Augmenix, Inc., a privately-held company that developed and commercialized the SpaceOAR® Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer.

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Announces Agreement To Acquire Augmenix, Inc.

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the SpaceOAR® System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.

Metro Business Network